Pancreatic Cancer Clinical Trials in San Francisco, California

7 studies are recruiting for pancreatic cancer in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

   The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Locations

   74 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07252232 on ClinicalTrials.gov

2. Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   49 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07491445 on ClinicalTrials.gov

3. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

   This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF, San Francisco, California

   Locations

   21 in total

   Run by

   ArriVent BioPharma, Inc.

   See if you can join NCT07066657 on ClinicalTrials.gov

4. A Study of DM002 in Patients With Advanced Solid Tumors

   The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco Cancer Center, San Francisco, California

   Locations

   7 in total

   Run by

   Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

   See if you can join NCT06751329 on ClinicalTrials.gov

5. Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)

   This is a feasibility, safety, tolerability, and efficacy research study of an investigational device called "Suizenji", an ultrasound-guided high-intensity focused ultrasound (HIFU) therapy system for the treatment of unresectable pancreatic ductal adenocarcinoma. Focused ultrasound therapy uses a…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Stanford University, San Francisco, California

   Run by

   SONIRE Therapeutics Inc.

   See if you can join NCT07033689 on ClinicalTrials.gov

6. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

   The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   26 in total

   Run by

   Frontier Medicines Corporation

   See if you can join NCT06244771 on ClinicalTrials.gov

7. UCSF PANC Cyst Registry

   Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are benign. Increased detection of pancreatic cysts provi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT04291651 on ClinicalTrials.gov